治験レーダーAI | ||
|---|---|---|
治験 NCT06573593（対象：円形脱毛症、Janus Kinase Inhibitors）は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study 150 RWE
治験（臨床試験）の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします！「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT06573593 は 観察研究 臨床試験 で、円形脱毛症、Janus Kinase Inhibitors に関するものです。現在は 募集中 で、2024年7月29日 から開始しています。150 名の参加者 の募集が計画されています。この試験は Second Affiliated Hospital, School of Medicine, Zhejiang University によって主導され、2026年12月31日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2024年8月27日 です。
概要
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disea...もっと見る
公式タイトル
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
疾患名
円形脱毛症Janus Kinase Inhibitorsその他の研究識別子
- 20240699
群（アーム）／介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
Tofacitinib treated group In the real-world settings, patients with AA treated with tofacitinib. | Tofacitinib In the real-world settings, patients with AA treated with tofacitinib. |
Baritinib treated group In the real-world settings, patients with AA treated with baritinib. | Baricitinib In the real-world settings, patients with AA treated with Baricitinib. |
Ruxolitinib treated group In the real-world settings, patients with AA treated with ruxolitinib | ルキソリチニブ In the real-world settings, patients with AA treated with Ruxolitinib. |
Upadacitinib treated group In the real-world settings, patients with AA treated with upadacitinib. | ウパダシチニブ In the real-world settings, patients with AA treated with Upadacitinib. |
Abrocitinib treated group In the real-world settings, patients with AA treated with abhicitinib. | Abrocitinib In the real-world settings, patients with AA treated with Abrocitinib. |
Ritlecitinib treated group In the real-world settings, patients with AA treated with ritlecitinib. | Ritlecitinib In the real-world settings, patients with AA treated with Ritlecitinib. |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Mean SALT | Reduction of Severity of Alopecia Tool (SALT) score compared with baseline | at week 24 |
SALT50 | Percentage of patient with more than 50% improvement in SALT score | at week 24 |
SALT75 | Percentage of patient with more than 70% improvement in SALT score | at week 24 |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Mean SALT | Reduction of Severity of Alopecia Tool (SALT) score compared with baseline | at week 12, 36, 48, 56 |
SALT50 | Percentage of patient with more than 75% improvement in SALT score | at week 12, 36, 48, 56 |
SALT75 | Percentage of patient with more than 50% improvement in SALT score | at week 12, 36, 48, 56 |
Safety profile | Any adverse events including infection, hypohepatia, thrombus, gastrointestinal reaction and any other system events. | at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 |
参加アシスタント
適格基準
対象年齢
小児, 成人, 高齢者
試験の最低年齢
2 Years
対象性別
全て
- Patients with alopecia areata between 2 to 18 years old
- Patients diagnosed with alopecia areata according to AA guideline
- AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
- Patients had previously received hair implants
- Other alopecia
- Other diseases may induce alopecia including psoriasis, lichen planus, et al.
- Unable to estimate SALT score at baseline or at follow-up
- Patients are participating in other clinical trials
Second Affiliated Hospital, School of Medicine, Zhejiang University試験中央連絡先
連絡先: Ru Dai, MD, 15982215914, [email protected]
連絡先: Wu, [email protected]
1 1カ国の場所
Zhejiang
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, 310009, China
Ru Dai, Ph.D, 連絡先, 86 15982215914, [email protected]
募集中